{"protocolSection":{"identificationModule":{"nctId":"NCT03080454","orgStudyIdInfo":{"id":"15-110"},"organization":{"fullName":"Northwell Health","class":"OTHER"},"briefTitle":"The Role of Trans-spinal Direct Current Stimulation (tsDCS) in Treating Patients With Hand Spasticity After Stroke","officialTitle":"The Effect of Treatment With the PathMaker Myoregulator Neuromodulation System Incorporating Trans-spinal Direct Current Stimulation (tsDCS) in Patients With Severe Hand Spasticity After Stroke"},"statusModule":{"statusVerifiedDate":"2019-08","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2016-09"},"primaryCompletionDateStruct":{"date":"2018-03","type":"ACTUAL"},"completionDateStruct":{"date":"2018-03","type":"ACTUAL"},"studyFirstSubmitDate":"2017-03-06","studyFirstSubmitQcDate":"2017-03-09","studyFirstPostDateStruct":{"date":"2017-03-15","type":"ACTUAL"},"resultsFirstSubmitDate":"2019-02-22","resultsFirstSubmitQcDate":"2019-08-06","resultsFirstPostDateStruct":{"date":"2019-09-13","type":"ACTUAL"},"lastUpdateSubmitDate":"2021-03-08","lastUpdatePostDateStruct":{"date":"2021-04-05","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Bruce Volpe","investigatorTitle":"Principal Investigator","investigatorAffiliation":"Northwell Health"},"leadSponsor":{"name":"Northwell Health","class":"OTHER"},"collaborators":[{"name":"PathMaker Neurosystems Inc.","class":"INDUSTRY"},{"name":"Dr. Zaghloul Ahmed","class":"UNKNOWN"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this study is to evaluate if 5 consecutive sessions of PathMaker anodal DoubleStim treatment, which combines non-invasive stimulation of the spinal cord (tsDCS- trans-spinal direct current stimulation) and of the median nerve at the peripheral wrist (pDCS-- peripheral direct current stimulation), can significantly reduce spasticity of the wrist and hand after stroke."},"conditionsModule":{"conditions":["Stroke","Cerebrovascular Accident (CVA)","Hemiparesis","Spasticity as Sequela of Stroke","Muscle Spasticity","Upper Extremity Paralysis"],"keywords":["stroke","CVA","Spasticity","hemiparesis","rehabilitation","trans-spinal direct current stimulation (tsDCS)","non-invasive stimulation"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"CROSSOVER","interventionModelDescription":"All participants received both stimulation conditions (sham Doublestim and anodal Doublestim), separated by a 1-week washout period.","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"SINGLE","maskingDescription":"The sham stimulation condition preceded the anodal stimulation condition for all participants, and subjects were told they would receive both conditions, but were blinded to order of assignment.","whoMasked":["PARTICIPANT"]}},"enrollmentInfo":{"count":26,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Sham Doublestim","type":"PLACEBO_COMPARATOR","description":"Participants first received 5 daily, consecutive 20 min sessions of sham Doublestim (trans-spinal direct current stimulation + peripheral direct current stimulation). After a washout period of 1 week, they then received 5 daily, consecutive 20 min sessions of anodal Doublestim (trans-spinal direct current stimulation + peripheral direct current stimulation). For all participants, the sham condition preceded the anodal Doublestim condition.","interventionNames":["Device: sham Doublestim"]},{"label":"Anodal Doublestim","type":"ACTIVE_COMPARATOR","description":"Participants first received 5 daily, consecutive 20 min sessions of sham Doublestim (trans-spinal direct current stimulation + peripheral direct current stimulation). After a washout period of 1 week, they then received 5 daily, consecutive 20 min sessions of anodal Doublestim (trans-spinal direct current stimulation + peripheral direct current stimulation). For all participants, the sham condition preceded the anodal Doublestim condition.","interventionNames":["Device: anodal Doublestim"]}],"interventions":[{"type":"DEVICE","name":"sham Doublestim","description":"PathMaker MyoRegulator device","armGroupLabels":["Sham Doublestim"],"otherNames":["sham trans-spinal direct current stimulation + peripheral direct current stimulation (tsDCS + pDCS)"]},{"type":"DEVICE","name":"anodal Doublestim","description":"PathMaker MyoRegulator device","armGroupLabels":["Anodal Doublestim"],"otherNames":["anodal trans-spinal direct current stimulation + peripheral direct current stimulation (tsDCS + pDCS)"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Mean Percent Change From Baseline in Area Under the Curve for Objectively Measured Spastic Catch Response of the Wrist Flexors at Fast Speed","description":"Subjects' wrists were passively extended at fast speed by a stepper motor to induce a spastic catch response, and its resistance torque was calculated in Newton meters (Nm). Mean percent change from baseline in the area under the curve for the resistance torque were compared across two timepoints (final session at day 5 and 1 week follow-up) in two conditions (sham vs. anodal Doublestim)","timeFrame":"baseline, final session at day 5, 1 week FU"}],"secondaryOutcomes":[{"measure":"Mean Modified Tardieu Scale (MTS) Score","description":"The Modified Tardieu Scale (MTS) quantifies muscle spasticity for each joint at slow and fast velocities on a 0-5 point scale. MTS scores at fast velocity were summed across 11 joints of the upper extremity (for a total of 0-55 points), with lower scores indicating improved spasticity. Mean summed MTS scores (out of 55 total points) were compared across two timepoints (final session at day 5 and 1 week FU) in two conditions (sham vs. anodal Doublestim).","timeFrame":"baseline, final session at day 5, 1 week FU"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. First single focal unilateral hemisphere lesion with diagnosis verified by brain imaging (MRI or CT scans) that occurred at least 6 months prior\n2. Cognitive function sufficient to understand the experiments and follow instructions\n3. A Modified Ashworth Scale score between 1-3 points for wrist flexor and extensor muscles\n4. A minimum of 15 degrees wrist passive range of motion (ROM) for wrist flexion and extension from wrist neutral position\n\nExclusion Criteria:\n\n1. Focal brainstem or thalamic infarcts\n2. Prior surgical treatments for spasticity of the upper limb\n3. Ongoing use of central nervous system (CNS)-active medications\n4. Ongoing use of psychoactive medications, such as stimulants, antidepressants, and anti-psychotic medications\n5. Botox or phenol alcohol treatment within 12 weeks of enrollment\n6. Pregnancy in women, as determined by self-report\n7. History of spinal cord injury or weakness\n8. Chronic pain\n9. Peripheral neuropathy including insulin dependent diabetes as determined by case history\n10. Presence of additional potential tsDCS risk factors:\n\n    * Damaged skin at the site of stimulation (i.e., skin with ingrown hairs, acne, razor nicks, wounds that have not healed recent scar tissue, broken skin, etc.)\n    * Presence of an electrically, magnetically or mechanically activated implant (including cardiac pacemaker), an intracerebral vascular clip, or any other electrically sensitive support system\n    * Highly conductive metal in any part of the body, including metal injury to the eye (jewelry must be removed during stimulation)\n    * Past history of seizures or unexplained spells of loss of consciousness during the previous 36 months","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Feinstein Institute for Medical Research","city":"Manhasset","state":"New York","zip":"11030","country":"United States","geoPoint":{"lat":40.79788,"lon":-73.69957}}]},"referencesModule":{"references":[{"pmid":"24478352","type":"BACKGROUND","citation":"Ahmed Z. Trans-spinal direct current stimulation alters muscle tone in mice with and without spinal cord injury with spasticity. J Neurosci. 2014 Jan 29;34(5):1701-9. doi: 10.1523/JNEUROSCI.4445-13.2014."},{"pmid":"25263206","type":"BACKGROUND","citation":"Ahmed Z. Trans-spinal direct current stimulation modifies spinal cord excitability through synaptic and axonal mechanisms. Physiol Rep. 2014 Sep 28;2(9):e12157. doi: 10.14814/phy2.12157. Print 2014 Sep 1."},{"pmid":"27932680","type":"BACKGROUND","citation":"Samaddar S, Vazquez K, Ponkia D, Toruno P, Sahbani K, Begum S, Abouelela A, Mekhael W, Ahmed Z. Transspinal direct current stimulation modulates migration and proliferation of adult newly born spinal cells in mice. J Appl Physiol (1985). 2017 Feb 1;122(2):339-353. doi: 10.1152/japplphysiol.00834.2016. Epub 2016 Dec 8."},{"pmid":"20153248","type":"BACKGROUND","citation":"Winkler T, Hering P, Straube A. Spinal DC stimulation in humans modulates post-activation depression of the H-reflex depending on current polarity. Clin Neurophysiol. 2010 Jun;121(6):957-61. doi: 10.1016/j.clinph.2010.01.014. Epub 2010 Feb 11."},{"pmid":"24970753","type":"BACKGROUND","citation":"Bocci T, Vannini B, Torzini A, Mazzatenta A, Vergari M, Cogiamanian F, Priori A, Sartucci F. Cathodal transcutaneous spinal direct current stimulation (tsDCS) improves motor unit recruitment in healthy subjects. Neurosci Lett. 2014 Aug 22;578:75-9. doi: 10.1016/j.neulet.2014.06.037. Epub 2014 Jun 23."},{"pmid":"21576030","type":"BACKGROUND","citation":"Truini A, Vergari M, Biasiotta A, La Cesa S, Gabriele M, Di Stefano G, Cambieri C, Cruccu G, Inghilleri M, Priori A. Transcutaneous spinal direct current stimulation inhibits nociceptive spinal pathway conduction and increases pain tolerance in humans. Eur J Pain. 2011 Nov;15(10):1023-7. doi: 10.1016/j.ejpain.2011.04.009. Epub 2011 May 14."},{"pmid":"18786856","type":"BACKGROUND","citation":"Cogiamanian F, Vergari M, Pulecchi F, Marceglia S, Priori A. Effect of spinal transcutaneous direct current stimulation on somatosensory evoked potentials in humans. Clin Neurophysiol. 2008 Nov;119(11):2636-40. doi: 10.1016/j.clinph.2008.07.249. Epub 2008 Sep 10."},{"pmid":"32232101","type":"DERIVED","citation":"Paget-Blanc A, Chang JL, Saul M, Lin R, Ahmed Z, Volpe BT. Non-invasive treatment of patients with upper extremity spasticity following stroke using paired trans-spinal and peripheral direct current stimulation. Bioelectron Med. 2019 Jul 23;5:11. doi: 10.1186/s42234-019-0028-9. eCollection 2019."}]},"ipdSharingStatementModule":{"ipdSharing":"UNDECIDED"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"All participants received both the anodal and sham trans-spinal direct current stimulation + peripheral direct current stimulation (tsDCS + pDCS) conditions, and sequence of stimulation conditions was the same across participants, with sham stimulation preceding active stimulation.","groups":[{"id":"FG000","title":"Sham Doublestim, Then Anodal Doublestim","description":"Participants underwent 2-3 baseline evaluations, then received 5 daily, consecutive 20 min sessions of sham Doublestim (trans-spinal direct current stimulation + peripheral direct current stimulation). After a washout period of 1 week, sham FU measures were collected. Participants then received 5 daily, consecutive 20 min sessions of anodal Doublestim (trans-spinal direct current stimulation + peripheral direct current stimulation), and again underwent follow-up measures 1 week after the anodal intervention. For all participants, the sham condition preceded the anodal Doublestim condition."}],"periods":[{"title":"Baseline","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"26"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","comment":"Two participants (pts) dropped out after consent due to hospitalizations unrelated to the study.","numSubjects":"24"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"2"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"2"}]}]},{"title":"Sham Doublestim (5days)","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"24"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"24"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"}]}]},{"title":"Sham FU (7days)","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"24"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"24"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"}]}]},{"title":"Anodal Doublestim (5 Days)","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"24"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"23"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"1"}]}]},{"title":"Anodal FU (7 Days)","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"23"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"19"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"4"}]}],"dropWithdraws":[{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"4"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Sham Doublestim, Then Anodal Doublestim","description":"Crossover design study: Participants first received 5 daily, consecutive 20 min sessions of sham Doublestim (trans-spinal direct current stimulation + peripheral direct current stimulation). After a washout period of 1 week, they then received 5 daily, consecutive 20 min sessions of anodal Doublestim (trans-spinal direct current stimulation + peripheral direct current stimulation)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"26"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"12"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"14"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"10"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"16"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"2"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"2"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"20"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"2"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"26"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Percent Change From Baseline in Area Under the Curve for Objectively Measured Spastic Catch Response of the Wrist Flexors at Fast Speed","description":"Subjects' wrists were passively extended at fast speed by a stepper motor to induce a spastic catch response, and its resistance torque was calculated in Newton meters (Nm). Mean percent change from baseline in the area under the curve for the resistance torque were compared across two timepoints (final session at day 5 and 1 week follow-up) in two conditions (sham vs. anodal Doublestim)","populationDescription":"Three subjects (out of 19) were found to be significant outliers for normality testing, and were consequently removed from analysis.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"percent change","timeFrame":"baseline, final session at day 5, 1 week FU","groups":[{"id":"OG000","title":"Sham Doublestim","description":"Participants first received 5 daily, consecutive 20 min sessions of sham Doublestim (trans-spinal direct current stimulation + peripheral direct current stimulation). After a washout period of 1 week, they then received 5 daily, consecutive 20 min sessions of anodal Doublestim (trans-spinal direct current stimulation + peripheral direct current stimulation). For all participants, the sham condition preceded the anodal Doublestim condition."},{"id":"OG001","title":"Anodal Doublestim","description":"Participants first received 5 daily, consecutive 20 min sessions of sham Doublestim (trans-spinal direct current stimulation + peripheral direct current stimulation). After a washout period of 1 week, they then received 5 daily, consecutive 20 min sessions of anodal Doublestim (trans-spinal direct current stimulation + peripheral direct current stimulation). For all participants, the sham condition preceded the anodal Doublestim condition."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"16"}]}],"classes":[{"title":"Mean percent change at final session (day 5)","categories":[{"measurements":[{"groupId":"OG000","value":"13.678","spread":"5.537"},{"groupId":"OG001","value":"-8.783","spread":"4.911"}]}]},{"title":"Mean percent change at 1 week follow-up (FU)","categories":[{"measurements":[{"groupId":"OG000","value":"15.927","spread":"5.537"},{"groupId":"OG001","value":"-16.333","spread":"6.180"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"EQUIVALENCE","nonInferiorityComment":"Statistical analysis for mean percent change from baseline in area under the curve for the resistance torque measure across 2 conditions (anodal vs. sham Doublestim) and at 2 timepoints (final session at day 5 and 1 week FU). Null hypothesis is that there was no difference in mean percent change in area under the curve between anodal and sham Doublestim conditions. A significance level of 0.05 was used (two-sided).","pValue":"0.004","pValueComment":"A 2x2 repeated measures ANOVA was performed with condition (mean percent change in anodal vs. sham condition) and time (final session at day 5 and 1 week FU in each condition) as factors. A significance level of 0.05 was used (two-sided).","statisticalMethod":"ANOVA"}]},{"type":"SECONDARY","title":"Mean Modified Tardieu Scale (MTS) Score","description":"The Modified Tardieu Scale (MTS) quantifies muscle spasticity for each joint at slow and fast velocities on a 0-5 point scale. MTS scores at fast velocity were summed across 11 joints of the upper extremity (for a total of 0-55 points), with lower scores indicating improved spasticity. Mean summed MTS scores (out of 55 total points) were compared across two timepoints (final session at day 5 and 1 week FU) in two conditions (sham vs. anodal Doublestim).","populationDescription":"Three subjects (out of 19) were found to be significant outliers for normality testing, and were consequently removed from analysis.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"scores on a scale","timeFrame":"baseline, final session at day 5, 1 week FU","groups":[{"id":"OG000","title":"Sham Doublestim","description":"Participants first received 5 daily, consecutive 20 min sessions of sham Doublestim (trans-spinal direct current stimulation + peripheral direct current stimulation). After a washout period of 1 week, they then received 5 daily, consecutive 20 min sessions of anodal Doublestim (trans-spinal direct current stimulation + peripheral direct current stimulation). For all participants, the sham condition preceded the anodal Doublestim condition."},{"id":"OG001","title":"Anodal Doublestim","description":"Participants first received 5 daily, consecutive 20 min sessions of sham Doublestim (trans-spinal direct current stimulation + peripheral direct current stimulation). After a washout period of 1 week, they then received 5 daily, consecutive 20 min sessions of anodal Doublestim (trans-spinal direct current stimulation + peripheral direct current stimulation). For all participants, the sham condition preceded the anodal Doublestim condition."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"16"}]}],"classes":[{"title":"mean score at final session (day 5)","categories":[{"measurements":[{"groupId":"OG000","value":"23.375","spread":"0.275"},{"groupId":"OG001","value":"21.625","spread":"0.275"}]}]},{"title":"mean score at 1 week FU","categories":[{"measurements":[{"groupId":"OG000","value":"23.125","spread":"0.275"},{"groupId":"OG001","value":"21.975","spread":"0.309"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"EQUIVALENCE","nonInferiorityComment":"Statistical analysis for mean Tardieu Scale Score summed across 11 joints of the upper extremity in 2 conditions (anodal vs. sham Doublestim) and at 2 timepoints (final session at day 5 and 1 week FU). Null hypothesis is that there was no difference in mean change between anodal and sham Doubleestim conditions. A significance level of 0.05 was used (two-sided).","pValue":"0.003","pValueComment":"A 2x2 repeated measures ANOVA was performed with condition (mean score in anodal vs. sham condition) and time (final session at day 5 and 1 week FU in each condition) as factors. A significance level of 0.05 was used (two-sided).","statisticalMethod":"ANOVA"}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"eight weeks for each subject","description":"Safety population included all participants who enrolled in study.","eventGroups":[{"id":"EG000","title":"Baseline","description":"Prior to any treatment interventions, participants performed 2-3 clinical and objective measure baseline evaluations.","deathsNumAffected":0,"deathsNumAtRisk":26,"seriousNumAffected":2,"seriousNumAtRisk":26,"otherNumAffected":0,"otherNumAtRisk":26},{"id":"EG001","title":"Sham Doublestim (5 Days) + Sham FU (7days)","description":"Following baseline evaluations, participants first received 5 daily, consecutive 20 min sessions of sham Doublestim (trans-spinal direct current stimulation + peripheral direct current stimulation). After a washout period of 1 week, they received a sham follow-up (FU) measure 7 days post-sham stimulation. Participants then received 5 daily, consecutive 20 min sessions of anodal Doublestim (trans-spinal direct current stimulation + peripheral direct current stimulation), followed by an anodal FU measure 7 days post-anodal Doublestim.","deathsNumAffected":0,"deathsNumAtRisk":24,"seriousNumAffected":0,"seriousNumAtRisk":24,"otherNumAffected":0,"otherNumAtRisk":24},{"id":"EG002","title":"Anodal Doublestim (5 Days) + Anodal FU (7days)","description":"Following baseline evaluations, participants first received 5 daily, consecutive 20 min sessions of sham Doublestim (trans-spinal direct current stimulation + peripheral direct current stimulation). After a washout period of 1 week, they received a sham follow-up (FU) measure 7 days post-sham stimulation. Participants then received 5 daily, consecutive 20 min sessions of anodal Doublestim (trans-spinal direct current stimulation + peripheral direct current stimulation), followed by an anodal FU measure 7 days post-anodal Doublestim.","deathsNumAffected":0,"deathsNumAtRisk":24,"seriousNumAffected":2,"seriousNumAtRisk":24,"otherNumAffected":1,"otherNumAtRisk":24}],"seriousEvents":[{"term":"hypotensive vasovagal event","organSystem":"Vascular disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"A hypotensive vasovagal event (fainting episode) that occurred during a baseline clinical evaluation prior to any treatment sessions. The subject was excluded from the study and the event was judged not related to the device.","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Hip fracture","organSystem":"Injury, poisoning and procedural complications","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Subject experienced an unrelated fall and hip fracture at home prior to receiving any stimulus in the study (sham or active), resulting in hospitalization and exclusion from the study.","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"seizure","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"2 subjects experienced a seizure 3-4 days after the fifth (final) active stimulation session. Both events were reported and deemed unrelated to study intervention.","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":24}]}],"otherEvents":[{"term":"persistent skin redness","organSystem":"Injury, poisoning and procedural complications","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Subject experienced moderate-severe neck redness immediately following stimulation, with persistent mild neck redness 24 later. Given the durability of her neck redness, the subject was excluded from the study by the PI.","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":24}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Bruce Volpe","organization":"Feinstein Institute for Medical Research at Northwell Health","email":"bvolpe1@northwell.edu","phone":"516-562-3384"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2017-08-18","uploadDate":"2019-05-29T10:59","filename":"Prot_SAP_000.pdf","size":362025},{"typeAbbrev":"ICF","hasProtocol":false,"hasSap":false,"hasIcf":true,"label":"Informed Consent Form","date":"2017-08-18","uploadDate":"2021-03-08T11:54","filename":"ICF_001.pdf","size":502804}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000009128","term":"Muscle Spasticity"},{"id":"D000020521","term":"Stroke"},{"id":"D000010243","term":"Paralysis"},{"id":"D000010291","term":"Paresis"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000009135","term":"Muscular Diseases"},{"id":"D000009140","term":"Musculoskeletal Diseases"},{"id":"D000009122","term":"Muscle Hypertonia"},{"id":"D000020879","term":"Neuromuscular Manifestations"},{"id":"D000009461","term":"Neurologic Manifestations"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M12847","name":"Paralysis","asFound":"Paralysis","relevance":"HIGH"},{"id":"M11775","name":"Muscle Spasticity","asFound":"Spasticity","relevance":"HIGH"},{"id":"M20634","name":"Muscle Weakness","relevance":"LOW"},{"id":"M12894","name":"Paresis","asFound":"Hemiparesis","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M11782","name":"Muscular Diseases","relevance":"LOW"},{"id":"M11787","name":"Musculoskeletal Diseases","relevance":"LOW"},{"id":"M11769","name":"Muscle Hypertonia","relevance":"LOW"},{"id":"M22309","name":"Neuromuscular Manifestations","relevance":"LOW"},{"id":"M12094","name":"Neurologic Manifestations","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"BC05","name":"Musculoskeletal Diseases"}]}},"hasResults":true}